NYCTCM Institutional Review Board

The NYCTCM Institutional Review Board has responsibility for the review of research involving human subjects for the NYCTCM. IRB members are drawn from various disciplines across New York and Philadelphia. The IRB is registered with OHRP: IRB00009353. The expiration date for our IORG-IRB Registration is 9/13/2025.

Membership Status  Name Degrees Representative Capacity
 Relationship With NYCTCM
 Chairman Thomas Burgoon MD  Scientific  Nonaffiliated
 Primary Voting Member  Sharon Zhao PhD  Scientific  NYCTCM
 Primary Voting Member  Yali Li MD/PhD  Scientific  Nonaffiliated
 Primary Voting Member  Bin Xu PhD  Scientific  NYCTCM
 Primary Voting Member  Charlie Tang Engineering  Nonscientific  Nonaffiliated
Alternate Voting Member Dong-Hua Yang PhD Scientific NYCTCM

IRB Functions
The IRB is responsible for the following oversight functions:

  1. Determine what activities constitute human participant research.
  2. Review, approve, require modifications in (to secure approval), or disapprove all research activities covered by this policy prior to the commencement of the research.
  3. Require that information given to participants as part of informed consent is in accordance with appropriate laws, regulations, and international standards. The IRB may require that additional information be given to the participants when, in the IRB’s judgment, the information would meaningfully add to the protection of the rights and welfare of participants.
  4. Require documentation of informed consent or waive documentation in accordance with federal and New York State laws and regulations. When research activities are being proposed to be conducted in other states and/or countries by NYCTCM, staff, and/or students, the research activities will be approved in compliance with the regulations for those specific research locations.
  5. Notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity. If the IRB decides to disapprove a research activity, it shall include in its written notification a statement of the reasons for its decision and give the investigator an opportunity to respond in person or in writing.
  6. Conduct continuing review of research covered by this policy at intervals appropriate to the degree of risk, but not less than once per year, (unless the research has been classified as “Exempt”) and have authority to observe or have a third party observe the consent process and the research.
  7. Suspend or terminate approval of research that is not being conducted in accordance with the IRB’s requirements or that has been associated with unexpected serious harm to participants. Any suspension or termination of approval shall include a statement of the reasons for the IRB’s action and shall be reported promptly to the investigator, appropriate institutional official and the department or agency head.

Review & Processing Time for a New Study
It takes an average of 15 calendar days from the time a new study is received by the IRB office to the date of presentation at a convened IRB meeting.

IRB Chair
Dr Thomas Burgoon
1217 West Chester Pike West Chester, PA 19382
Office: 610.329.1521 Cell: 610.431.0850
Email: tburgoonmd@gmail.com